Inflammation as target in cancer therapy
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, přehledy
Grantová podpora
Cancer Research UK - United Kingdom
PubMed
28618326
DOI
10.1016/j.coph.2017.05.007
PII: S1471-4892(17)30056-5
Knihovny.cz E-zdroje
- MeSH
- lidé MeSH
- makrofágy imunologie MeSH
- nádorové mikroprostředí imunologie MeSH
- nádory farmakoterapie imunologie MeSH
- zánět farmakoterapie imunologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Cells of the innate immunity infiltrating tumour tissues promote, rather than halt, cancer cell proliferation and distant spreading. Tumour-Associated Macrophages (TAMs) are abundantly present in the tumour milieu and here trigger and perpetrate a state of chronic inflammation which ultimately supports disease development and contributes to an immune-suppressive environment. Therapeutic strategies to limit inflammatory cells and their products have been successful in pre-clinical tumour models. Early clinical trials with specific cytokine and chemokine inhibitors, or with strategies designed to target TAMs, are on their way in different solid malignancies. Partial clinical responses and stabilization of diseases were observed in some patients, in the absence of significant toxicity. These encouraging results open new perspectives of combination treatments aimed at reducing cancer-promoting inflammation to maximize the anti-tumour efficacy.
Institute of Microbiology Czech Academy of Sciences Prague Czech Republic
IRCCS Istituto Clinico Humanitas Rozzano Milan Italy
IRCCS Istituto Clinico Humanitas Rozzano Milan Italy; Università Piemonte Orientale Novara Italy
Citace poskytuje Crossref.org
Spontaneous and Induced Tumors in Germ-Free Animals: A General Review